Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Functional fitness of CAR-T cells in the bone marrow following anti-BCMA durcabtagene autoleucel (PHE885) therapy correlate with prolonged PFS in RRMM

View Full Paper
Ask AI
Bookmark
Share

Authors

LPLakshmi Bhavani PotluriHSHannah SeahSVSahan D. Vangala

Discussion

Loading...

Member takes

Overview

Phase 1 trial demonstrates improved T-cell activation and anti-tumor activity in RRMM patients, indicating potential for prolonged responses.

Key Points

  • To assess the functional fitness of CAR-T cells in bone marrow and its correlation with prolonged progression-free survival in RRMM patients receiving anti-BCMA therapy.
  • Conducted a phase 1 clinical trial with 55 RRMM patients treated with PHE885 CAR-T cell therapy.
  • Performed immune-monitoring evaluations of CAR-T cell activation and functionality in bone marrow using CyTOF analysis.
  • Compared CAR-T cell characteristics between patients achieving sustained complete response (sCR) and those who progressed.
  • Assessed regulatory T cell populations and various activation markers on CAR-T cells.
  • Overall response rate was found to be 98%, with a complete response rate of 55%.
  • Significant differences in regulatory T cell populations were observed between patients with sCR and those with disease progression.
  • sCR patients exhibited higher expression of activation markers (CD38, CD28, CD27) and cytokines (IL-2, granzyme-B) compared to PD patients, suggesting enhanced anti-tumor activity.

Cite This Study

Potluri et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d676https://doi.org/10.1182/blood-2025-5713
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 3617: Expansion and persistence of anti-BCMA CAR T cells correlates with durability of responses in multiple myeloma patients2024
  2. 2Abstract 3980: Non-canonical CAR T cell states correlate with durable therapeutic responses in multiple myeloma patients2026
  3. 3Long-term follow-up of patients with relapsed/refractory multiple myeloma after BCMA CAR-T-cell therapy2025 · 3 citations
  4. 4Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma2024 · 67 citations
  5. 5Assessment of long-term persistence and phenotypic features of BCMA CAR-T cells in patients with relapsed or refractory multiple myeloma treated with ciltacabtagene autoleucel.2026